{"schema_version":"secwatch.filing_event.v1","accession":"0001062822-24-000051","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2024-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.064897+00:00","generated_at":"2026-05-31T04:28:37.074212+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Lexicon Pharma CFO/COO Jeffrey Wade to depart Sep 30; Kristen Alexander named principal financial officer","bullets":["Jeffrey Wade's employment as president, COO and principal financial officer terminates Sep 30, 2024.","Wade receives salary continuation of $585k for 12 months, lump sum $175.5k, COBRA $3.7k/mo for 12 months, plus outplacement.","Wade enters 8-month consulting agreement at $3,000/month starting after termination.","Kristen Alexander, VP finance and accounting and principal accounting officer since 2021, becomes principal financial officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001062822-24-000051","json":"https://secwatch.observer/filing/0001062822-24-000051.json","markdown":"https://secwatch.observer/filing/0001062822-24-000051.md","text":"https://secwatch.observer/filing/0001062822-24-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000106282224000051/0001062822-24-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000106282224000051/lxrx-20240913.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:28:37.074212+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7263978b76","claim":"Kristen L. Alexander was appointed as Principal Financial Officer at LEXICON PHARMACEUTICALS, INC..","evidence_excerpt":"Effective as of the date of termination of Mr. Wade’s employment, Kristen L. Alexander will assume the function of our principal financial officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282224000051/0001062822-24-000051-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Principal Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"a211f96573","claim":"Jeffrey L. Wade was terminated as President and Chief Operating Officer at LEXICON PHARMACEUTICALS, INC..","evidence_excerpt":"On September 13, 2024, we and Jeffrey L. Wade determined that his employment as our president and chief operating officer (in which capacity, Mr. Wade has functioned as our principal financial officer) would terminate as of September 30, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1062822/000106282224000051/0001062822-24-000051-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"President and Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}